GBT Announces New Employment Inducement Grants

These awards were made under GBTs Amended and Restated 2017 Inducement Equity Plan (the Plan).

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Monday, October 5, 2020

Information

Tags:

Branches of biology, Selectins, Proteins, Medical specialties, Health in Africa, Hematopathology, RTT, Sickle cell disease, Scd, Stearoyl-CoA desaturase-1, P-selectin, E-selectin

Geotags:

Organisation:

GLOBAL BLOOD THERAPEUTICS, INC.

Summary

Key Points:

These awards were made under GBTs Amended and Restated 2017 Inducement Equity Plan (the Plan).
The above-described awards were each granted as an inducement material to the employees entering into employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan.
Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder.
GBT is also advancing its pipeline program in SCD with inclacumab, a p-selectin inhibitor in development to address pain crises associated with the disease.

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on October 1, 2020, the compensation committee of GBT’s board of directors granted 20 new employees options to purchase an aggregate of 12,000 shares of the company’s common stock with a per share exercise price of $57.96 and restricted stock units for an aggregate of 93,950 shares of the company’s common stock. These awards were made under GBT’s Amended and Restated 2017 Inducement Equity Plan (the Plan).

The above-described awards were each granted as an inducement material to the employees entering into employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by GBT’s board of directors in January 2017 and has been amended and restated from time to time.

About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta^® (voxelotor), the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a p-selectin inhibitor in development to address pain crises associated with the disease. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Contact Information:
Steven Immergut (investors and media)
650-410-3258
[email protected]